myostatin inhibitor drugs - An Overview
BYM-338 is undoubtedly an antibody directed to ActRIIB that is at this time in Section two to the therapy of cachexia in people with phase IV nonsmall cell lung cancer or Phase III/IV adenocarcinoma of your pancreas. The first endpoint on the trial is TMV at 8 months as calculated by MRI.The authors of this manuscript certify which they comply with